Interpharma is actively engaged with its member companies seeking to develop new, innovative price models especially in the area of combination therapies and in the differing medical benefit in different indications of the same medicine. As a result of the rapid advances in medicine, especially in oncology, greater flexibility in needed in the established pricing model to make sure patients can also continue to have access to the latest treatments. Interpharma is engaged in dialogue with health insurers about reimbursing the cost of innovative combination treatments in oncology. Thanks to this dialogue, three combination therapies were included in the Specialties List (SL) in spring 2016. Interpharma remains committed to finding flexible and pragmatic solutions to secure access to the latest treatments.